ESM1 Promote Proliferation, Invasion and Angiogenesis Via Akt/mTOR and Ras Pathway in Kidney Renal Clear Cell Carcinoma

Overview

Journal Sci Rep

Date 2025 Feb 10

PMID 39929852

Authors

Jianjun Luo

Ting Yi

Yong Wang

Wei Song

Zhiyong Gao

Jiansong Wang

Yukun Li

Affiliations

Soon will be listed here.

Abstract

The most common types of renal carcinoma is kidney renal clear cell carcinoma (KIRC). ESM1 is a secreted protein, which involved in, lipids and glucose metabolism, but their role in angiogenesis is contradictory in different disease, especially in KIRC. Bioinformatic analysis confirmed the ESM1 expression and prognosis in KIRC. IHC staining revealed protein expression of ESM1 in KIRC samples. The role of ESM1 in KIRC proliferation and migration were tested by MTT, EdU, transwell analysis. The role of its paracrine function in KIRC angiogenesis was tested by functional experiments. The downstream molecular mechanism of ESM1 were further elucidated by WB and functional experiments. ESM1 was significantly increased in KIRC with prognostic significance. ESM1 knockdown inhibited the invasiveness capability and viability of KIRC cell. The paracrine of ESM1 enhanced HUVECs proliferation and migration to format tube in KIRC cell conditional medium. ESM1 knockdown induced the inactivation of Akt/mTOR and Ras pathway to attenuate proliferation, migration, invasion and angiogenesis in KIRC. ESM1 was a key role in the tumor microenvironment (TME) of KIRC, which promoted the proliferation, migration, invasion, and angiogenesis by activating Akt/mTOR and Ras pathway. It is a potential therapeutic target for KIRC patients.

References

Li J, Yang D, Zhang C, Wei S, Zhao R, Dai S . ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma. Biomed Res Int. 2022; 2022:5328192. PMC: 9348936. DOI: 10.1155/2022/5328192. View

Wang C, He Y, Zheng J, Wang X, Chen S . Dissecting order amidst chaos of programmed cell deaths: construction of a diagnostic model for KIRC using transcriptomic information in blood-derived exosomes and single-cell multi-omics data in tumor microenvironment. Front Immunol. 2023; 14:1130513. PMC: 10154557. DOI: 10.3389/fimmu.2023.1130513. View

Sanchez D, Simon M . Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochim Biophys Acta Rev Cancer. 2018; 1870(1):23-31. PMC: 6561085. DOI: 10.1016/j.bbcan.2018.06.003. View

Cheng T, Gu M, Xu W, Ye D, Zha Z, Fang W . Mechanism of lncRNA SNHG16 on kidney clear cell carcinoma cells by targeting miR-506-3p/ETS1/RAS/ERK molecular axis. Heliyon. 2024; 10(9):e30388. PMC: 11096951. DOI: 10.1016/j.heliyon.2024.e30388. View

Haunschild C, Tewari K . Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2019; 16(7):225-246. PMC: 7036749. DOI: 10.2217/fon-2019-0042. View

Li Y, Zeng T, Guan Y, Liu J, Liao N, Wang M . Validation of ESM1 Related to Ovarian Cancer and the Biological Function and Prognostic Significance. Int J Biol Sci. 2023; 19(1):258-280. PMC: 9760436. DOI: 10.7150/ijbs.66839. View

Bi K, He M, Bakouny Z, Kanodia A, Napolitano S, Wu J . Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 2021; 39(5):649-661.e5. PMC: 8115394. DOI: 10.1016/j.ccell.2021.02.015. View

Hu H, Chen Y, Tan S, Wu S, Huang Y, Fu S . The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment. Front Immunol. 2022; 13:802846. PMC: 8905241. DOI: 10.3389/fimmu.2022.802846. View

Lugano R, Ramachandran M, Dimberg A . Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2019; 77(9):1745-1770. PMC: 7190605. DOI: 10.1007/s00018-019-03351-7. View

10.

Yang L, Dong Z, Li S, Chen T . ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression. Aging (Albany NY). 2023; 15(8):2920-2936. PMC: 10188330. DOI: 10.18632/aging.204559. View

11.

Kang N, Liang X, Fan B, Zhao C, Shen B, Ji X . Endothelial-Specific Molecule 1 Inhibition Lessens Productive Angiogenesis and Tumor Metastasis to Overcome Bevacizumab Resistance. Cancers (Basel). 2022; 14(22). PMC: 9688485. DOI: 10.3390/cancers14225681. View

12.

He Y, Lin L, Ou Y, Hu X, Xu C, Wang C . Endothelial cell-specific molecule 1 (ESM1) promoted by transcription factor SPI1 acts as an oncogene to modulate the malignant phenotype of endometrial cancer. Open Med (Wars). 2022; 17(1):1376-1389. PMC: 9420884. DOI: 10.1515/med-2022-0529. View

13.

Zhang H, Shen Y, Zhang L, Chen J, Bian H, Gu W . Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach. Front Oncol. 2021; 11:687120. PMC: 8181400. DOI: 10.3389/fonc.2021.687120. View

14.

Liu W, Yang Y, He B, Ma F, Sun F, Guo M . ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway. Ann Transl Med. 2021; 9(7):533. PMC: 8105853. DOI: 10.21037/atm-20-7005. View

15.

Zheng W, Zhang S, Guo H, Chen X, Huang Z, Jiang S . Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma. Cell Commun Signal. 2021; 19(1):39. PMC: 7992844. DOI: 10.1186/s12964-021-00728-9. View

16.

Quail D, Joyce J . Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19(11):1423-37. PMC: 3954707. DOI: 10.1038/nm.3394. View

17.

Chae Y, Arya A, Iams W, Cruz M, Chandra S, Choi J . Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018; 6(1):39. PMC: 5956851. DOI: 10.1186/s40425-018-0349-3. View

18.

Martin J, Cabral H, Stylianopoulos T, Jain R . Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020; 17(4):251-266. PMC: 8272676. DOI: 10.1038/s41571-019-0308-z. View

19.

Li Y, Gao A, Zeng T, Liu D, Zhang Q, Ran X . ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1. J Transl Med. 2024; 22(1):46. PMC: 10785435. DOI: 10.1186/s12967-023-04819-8. View

20.

Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader G . GeneMANIA update 2018. Nucleic Acids Res. 2018; 46(W1):W60-W64. PMC: 6030815. DOI: 10.1093/nar/gky311. View